EANS-News: SYGNIS Pharma AG / SYGNIS announces the adaptation of its organisation to the new business activity

Heidelberg (euro adhoc) -

Corporate news transmitted by euro adhoc. The issuer/originator is solely responsible for the content of this announcement.

Strategic management decisions

Press Release

SYGNIS announces the adaptation of its organisation to the new business activity

Heidelberg 20 December 2012 - SYGNIS Pharma AG (Frankfurt: LIO1; ISIN:
DE000A1RFM03, Prime Standard) announced today the discontinuation of its therapeutic R&D project KIBRA and the adaptation of its organisation to the new business activity. At the Heidelberg site the staff will be reduced by 10 employees. These measures are implemented to concentrate the financial resources on the development and marketing of novel technologies in molecular biology in line with the new corporate strategy. This new business was acquired in 2012 by joining forces with the Spanish X-Pol Biotech.

Peter Willinger, Chief Financial Officer, stated: "Despite good progress in the project, an outlicensing of the KIBRA project was unfortunately not possible within the available timeline. The KIBRA project can not be continued with internal resources. The realignment of the company regrettably makes a staff reduction necessary. I would like to extend my sincere gratitude to all employees affected for their excellent work for SYGNIS."

For further information please contact:

SYGNIS Pharma AG
Peter Willinger
CFO
SYGNIS Pharma AG

Tel.: +49 6221 454 836
E-mail: peter.willinger@sygnis.de

About SYGNIS Pharma AG: www.sygnis.de

SYGNIS Pharma AG (Heidelberg, Germany) is a biotech company listed in the Prime Standard of the German Stock Exchange (Ticker: LIO1; ISIN: DE000A1RFM03). According to the 2012 newly defined business strategy, the company focuses on the development and marketing of novel technologies in molecular biology, e.g. in the field of DNA amplification and sequencing. For the key product "Qualiphi®", an improved polymerase for amplifying DNA, an exclusive worldwide license has been granted to Qiagen in July 2012.

### Disclaimer
Some statements included in this press release, relating neither to proven financial results nor other historical data, should be viewed as forward-looking, i.e. not definite. Such statements are mainly predictions of future results, trends, plans or goals. These statements should not be considered to be total guarantees since given their very nature they are subject to known and unknown risks and imponderability and can be affected by other factors as a consequence of which the actual results, plans and goals of SYGNIS Pharma AG may deviate greatly from the established conclusions or implied predictions contained in such statements. SYGNIS does not undertake to publicly update or revise these statements in the light of new information or future results or for any other reason. ###

end of announcement euro adhoc

company: SYGNIS Pharma AG Im Neuenheimer Feld 515 D-69120 Heidelberg phone: +49 (0)6221 454-6 FAX: +49 (0)6221 454-777 mail: contact@sygnis.de WWW: http://www.sygnis.de sector: Biotechnology ISIN: DE000A1RFM03 indexes:

stockmarkets:
language: English

Digital press kit: http://www.ots.at/pressemappe/EASY_65063/aom

Rückfragen & Kontakt:

Michael Wolf
Telefon: +49 (6221) 454 - 6
E-Mail: Michael.Wolf@sygnis.de

ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | CNE0002